![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: DHX57 |
Gene summary for DHX57 |
![]() |
Gene information | Species | Human | Gene symbol | DHX57 | Gene ID | 90957 |
Gene name | DExH-box helicase 57 | |
Gene Alias | DDX57 | |
Cytomap | 2p22.1 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q6P158 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
90957 | DHX57 | HCC1_Meng | Human | Liver | HCC | 2.45e-39 | 1.93e-02 | 0.0246 |
90957 | DHX57 | HCC2_Meng | Human | Liver | HCC | 4.12e-09 | 4.62e-03 | 0.0107 |
90957 | DHX57 | HCC2 | Human | Liver | HCC | 3.92e-02 | 1.36e+00 | 0.5341 |
90957 | DHX57 | HCC5 | Human | Liver | HCC | 2.37e-13 | 4.90e-01 | 0.4932 |
90957 | DHX57 | S014 | Human | Liver | HCC | 8.58e-04 | 2.70e-01 | 0.2254 |
90957 | DHX57 | S015 | Human | Liver | HCC | 4.40e-04 | 3.43e-01 | 0.2375 |
90957 | DHX57 | S016 | Human | Liver | HCC | 4.78e-10 | 3.82e-01 | 0.2243 |
90957 | DHX57 | S027 | Human | Liver | HCC | 1.29e-06 | 5.05e-01 | 0.2446 |
90957 | DHX57 | S029 | Human | Liver | HCC | 1.10e-04 | 3.21e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Breast | Precancer | ![]() |
Breast | IDC | ![]() |
Breast | DCIS | ![]() |
Cervix | CC | ![]() |
Cervix | HSIL_HPV | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DHX57 | SNV | Missense_Mutation | c.1022N>G | p.Ser341Cys | p.S341C | Q6P158 | protein_coding | deleterious(0.01) | probably_damaging(0.93) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
DHX57 | SNV | Missense_Mutation | novel | c.2764A>T | p.Ile922Phe | p.I922F | Q6P158 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A7-A425-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | adriamycin | PD |
DHX57 | SNV | Missense_Mutation | c.2806G>C | p.Glu936Gln | p.E936Q | Q6P158 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A8-A06Q-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
DHX57 | SNV | Missense_Mutation | c.8N>A | p.Ser3Tyr | p.S3Y | Q6P158 | protein_coding | deleterious_low_confidence(0) | benign(0.133) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
DHX57 | SNV | Missense_Mutation | c.3461G>C | p.Arg1154Thr | p.R1154T | Q6P158 | protein_coding | deleterious(0.01) | benign(0.007) | TCGA-AO-A0J4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
DHX57 | SNV | Missense_Mutation | c.1919N>A | p.Arg640Lys | p.R640K | Q6P158 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
DHX57 | SNV | Missense_Mutation | rs571716433 | c.1855N>A | p.Glu619Lys | p.E619K | Q6P158 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
DHX57 | SNV | Missense_Mutation | c.995N>A | p.Gly332Glu | p.G332E | Q6P158 | protein_coding | tolerated(0.6) | benign(0.355) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
DHX57 | SNV | Missense_Mutation | c.3082N>G | p.Pro1028Ala | p.P1028A | Q6P158 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
DHX57 | SNV | Missense_Mutation | c.793N>C | p.Glu265Gln | p.E265Q | Q6P158 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-GM-A2DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |